IL1B and COVID-19: As discussed here, blockade of IL-1 pathways has transformed the management of a spectrum of diseases, ranging from hyperinflammatory conditions associated with infections, such as COVID-19, to chronic immune-mediated disorders and smoldering chronic inflammation that fuels atherogenesis and tumor progression.